Hematological Malignancies

Durability of Clinical Responses with 90 Y Ibritumomab Tiuxetan

Time to progression in patients with long-term responses (TTP ≥12 months) to 90 Y ibritumomab tiuxetan (n = 78)

Patients Progression-F ree, % 100 90 80 70 60 50 40 30 20 10 0

Median TTP = 29.3 months

0

10

20

30

40

50

60

70

80

TTP, months

Wiseman GA, et al. Cancer Biother Radiopharm . 2005;20(2):185-188.